Clovis Oncology Announces Availability of Rubraca®▽ (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Germany | Business Wire
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration | Journal of Clinical Oncology
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial - ScienceDirect
Rucaparib: the past, present, and future of a newly approved PARP inhi | OTT
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo- controlled, phase 3 trial - The Lancet
National Ovarian Cancer Coalition on Twitter: "Breaking: Clovis Oncology's Rucaparib Significantly Improved Progression-Free Survival in OVC Populations #ARIEL3 https://t.co/vmCpVOl9PZ https://t.co/YK1769oREU" / Twitter
Pharmacological profile of olaparib, veliparib and rucaparib across 29... | Download Scientific Diagram
ASCO GU 2022: A Randomized, Double Blind, Biomarker Selected, Phase II Clinical Trial of Maintenance PARP Inhibition Following Chemotherapy for Metastatic Urothelial Carcinoma: Final Analysis of the ATLANTIS Rucaparib Arm
Rucaparib | ≥99%(HPLC) | Selleck | PARP inhibitor
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events | International Journal of Gynecologic Cancer
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial - The Lancet Respiratory Medicine
Table 4 from Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy | Semantic Scholar
ASCO GU 2020: Rucaparib for Recurrent, Locally Advanced, or Metastatic Urothelial Carcinoma (mUC): Results from ATLAS, A Phase II Open-Label Trial
Rucaparib: the past, present, and future of a newly approved PARP inhi | OTT
Clovis Oncology Announces Availability of Rubraca®▽ (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Germany | Business Wire
The PARP Inhibitor Rucaparib in the Maintenance Therapy of Recurrent Ovarian Carcinoma: Highlights from the ARIEL3 Clinical Trial
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma -
Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer. - Abstract - Europe PMC
Enrolling Clinical Trials: Rucaparib for the Treatment of Pancreatic Cancer - Penn Medicine
Platinum-Sensitive Recurrent Disease - PARPi in Ovarian Cancer - Module - PARPi in Ovarian Cancer - Oncology - Clinical Care Options
![PDF] Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/52c115c5bf799368014e6b136b39cae306751b37/3-Figure1-1.png "PDF] Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer | Semantic Scholar")
PDF] Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer | Semantic Scholar
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial - The Lancet Oncology
ESMO 2019: Preliminary Results from the TRITON2 Study of Rucaparib in Patients with DNA Damage Repair-deficient mCRPC: Updated Analyses
Rucaparib Shows Clinical Benefit as Maintenance Therapy in Patients with Recurrent Ovarian Cancer | ESMO
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) | Nature Communications
